IL18
EmergingIL-18 is an emerging marker helping distinguish HLH/MAS from other causes of severe inflammation, including CAR-T toxicity.
IL-18 is part of an inflammatory chain reaction seen in a serious immune overactivation condition called HLH. Very high levels, especially compared to another related marker, help doctors recognize this dangerous condition, which can occur after certain cancer immunotherapies.
Interleukin-18 (IL-18) is a pro-inflammatory cytokine involved in the interferon-gamma-driven inflammatory cascade, with particular relevance to hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
Markedly elevated IL-18, especially a high IL-18/CXCL9 ratio, is increasingly studied as a marker helping distinguish HLH/MAS from other causes of cytokine storm, including in the context of CAR-T cell therapy-related toxicity.
Measured via serum immunoassay, typically as part of a broader cytokine panel alongside ferritin, soluble CD25, and CXCL9 when HLH/MAS is suspected, connecting directly to the extreme hyperferritinemia discussion from earlier in this biomarker set.
Extremely elevated IL-18 in a critically ill patient supports more aggressive consideration of HLH/MAS-directed therapy (such as anakinra, an IL-1 receptor antagonist with some efficacy in this setting) alongside treatment of the underlying trigger.
The IL-18/CXCL9 ratio is a specific, actively-studied refinement for improving HLH/MAS diagnostic accuracy.
- General hematology/immunology reference literature on IL-18 in HLH/MAS diagnosis and CAR-T-related cytokine storm.